Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Daniel Nishijima, MD, MAS
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04387305CT.gov Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: An Efficacy Study | — | Not Yet Recruiting | — | — | — |
NCT06330935CT.gov Evaluating the Effect of Tranexamic Acid on the Clinical Outcomes in Patients With Traumatic Brain Injury | — | Unknown | — | — | — |
NCT04521881CT.gov Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults | — | Recruiting | — | — | — |
NCT02645552CT.gov Pre-hospital Administration of Tranexamic Acid for Moderate and Severe Traumatic Brain Injury | — | Unknown | — | — | — |
NCT01990768CT.gov Prehospital Tranexamic Acid Use for Traumatic Brain Injury | — | Completed | — | — | — |
NCT01402882CT.gov Clinical Randomisation of an Antifibrinolytic in Significant Head Injury | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Traumatic Brain Injury
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tranexamic Acid (this asset) | Daniel Nishijima, MD, MAS | P3 | BB · 64 |
| Melatonin | Children's National Research Institute | P4 | BBB |
| Apsolol | Tanta University | P4 | BBB |
| Nepenthe | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
| Amantadine | SHINKEI Therapeutics, Inc | P4 | BB |
| Dexmedetomidine | Universitas Jenderal Soedirman | P4 | BB |
| Fentanyl | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
| VENLOR | Virginia Commonwealth University | P4 | BB |
| Dextromethorphan | Avanir Pharmaceuticals | P4 | BB |
+42 more in the Traumatic Brain Injury cohort
Other indications for Tranexamic Acid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Intracerebral Hemorrhage | — | P4 | BB · 71 |
| Post-Operative Wound Seroma, Non-Human Animal | — | P4 | BB · 69 |
| Brain Injury | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tranexamic Acid in Traumatic Brain Injury. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tranexamic-acid-traumatic-brain-injury
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →